



Response Evaluation In Neurofibromatosis Schwannomatosis INTERNATIONAL COLLABORATION

- If sharing any data or information from these slides generated by the REiNS International Collaboration, please acknowledge the authors, group chairs, and specific working group.
- If using any information presented with a citation, please reference the primary source.

FDA Guidance on Decentralized Clinical Trials

REiNS Winter Meeting
December 4, 2023

Diana Bradford, MD
Division of Oncology 2, CDER, FDA

Decentralized Clinical Trials



DCT: a clinical trial where some or all of the trial-related activities occur at locations other than traditional clinical trial sites

Regulatory requirements for investigation of medical products are the same for DCTs and traditional trials

FDA draft guidance, Decentralized Clinical Trials for Drugs, Biological Products, and Devices, May 2023

Why are Regulators Interested?

- Accessibility
 - Patients with rare diseases
 - Patients with mobility or cognitive challenges
 - Diversity of participants (socio-economic, cultural)
- Patient convenience
- Efficiencies
 - Travel
 - Physical facilities
 - Use of qualified community providers
- Experience with COVID-19
 - Contagious diseases

Themes: FDA Guidance on DCTs



- Risk-adapted approach
 - What elements of decentralization are appropriate for a given investigation?
- Pre-specify decentralized elements
 - Documentation
- Regulatory requirements do not differ for DCTs

Strategies to Bring the Trial to the Patient



- Video and telemedicine visits
- Digital health technologies
- Direct distribution of products
- Electronic informed consent
- Home visits
- Use of local health care providers and facilities

DCT Design

- Remote assessments may differ from on-site assessments
- Assessments performed by local HCPs **may be more variable** and less precise than assessments conducted by trial personnel
- Consideration of the **statistical analysis** to be performed
- For inspectional purposes, there should be a physical location where **all clinical trial-related records** for participants under the investigator's care are accessible and where trial personnel can be interviewed

Remote Trial Visits and Activities

- Remote visits: can occur at locations such as a participant's home or a local healthcare facility
- Telehealth visits: can be considered by investigators
- Remote in-person visits and trial-related activities can be conducted by:
 - *trial personnel* who are sent to participants' homes or preferred locations
 - *local healthcare providers* (HCPs) who are located close to trial participants' homes

Local Healthcare Providers



- Local HCPs may be used by sponsors or investigators to perform certain trial-related activities
- Trial-related services provided by local HCPs should not differ from those that they are qualified to perform in clinical practice
 - Should not require a detailed knowledge of the protocol or the investigational product (IP)
 - Trial-related activities unique to research and/or require a detailed knowledge of the protocol or the IP should be performed by qualified trial personnel who have been appropriately trained

Digital Health Technologies

- Incorporation of the use of DHTs into clinical trials can support decentralization
- Sponsors should ensure that DHTs are available and suitable for use by all trial participants
- Draft guidance on DHTs published in December 2021: *Digital Health Technologies for Remote Data Acquisition in Clinical Investigations*

Sponsor's Role and Responsibilities



- **Sponsor responsibilities are the same** for DCTs and traditional site-based clinical trials
- Should strive for **diversity and inclusiveness** in trial populations
- Must account for multiple **sources of data collection** in a DCT in the data management plan
- Should describe in the trial protocol how operational aspects of the DCT will be implemented

Sponsor: Monitoring and Compliance



- Must ensure proper monitoring of the investigation
- May use a variety of approaches to monitor DCTs, and the monitoring plan for a trial should be based on the sponsor's risk assessment
- Must comply with relevant local laws, regulations, and licensing requirements governing medical practice and IP administration when conducting a DCT

Investigator's Role and Responsibilities

- Responsible for the conduct of the DCT and the oversight of individuals delegated to perform trial-related activities
 - A key difference for DCTs is the extent to which the investigator uses telehealth, trial personnel working remotely, local HCPs, and/or DHTs in the conduct of the trial
- Decentralized features **may necessitate additional training**, coordination, and standard operating procedures to ensure consistent implementation

Investigator Delegation of Activities



- When permitted by the trial protocol, **investigators may delegate trial-related activities to local HCPs** to perform trial-related procedures that require in-person interactions with trial participants
- A critical consideration when delegating trial-related activities to local HCPs is the **potential for variability** in the approach across different practices
- Videoconferencing and other technologies may be useful to allow investigators to oversee trial personnel performing activities described in the trial protocol at participants' locations

Documentation: Investigators, Subinvestigators, Local HCPs



- Drug trials (Form 1572)
 - When trial personnel contribute directly and significantly to the trial data, they should be included on Form FDA 1572 as subinvestigators
 - Local HCPs (as defined in the draft guidance) should not be listed on Form FDA 1572 as subinvestigators. However, local HCPs should be included in a task log.
- For device trials, local HCPs are generally not considered investigators and should not be included in the IDE list of investigators. However, these local HCPs should be included in a task log

Task Log

- Investigators must maintain a task log of local HCPs who perform trial-related activities
- Task log should include:
 - (1) The names and affiliations of the local HCPs
 - (2) Description of their roles and assigned tasks
 - (3) Dates these local HCPs are added to the log
 - (4) Locations where these activities are conducted
- Should be dated and signed by the investigator when initially created and updated when a new local HCP is added
- Should be available to FDA during inspections

Clinical Laboratory Facilities



- May use **designated** clinical laboratory facilities
- May permit use of **local laboratory facilities** close to the trial participant
- May allow **specimen collection by remote trial personnel**, local HCPs, or clinical laboratory facilities and send to designated facilities for processing
- All clinical laboratory facilities should be listed on Form FDA 1572 or in the investigational plan for device studies under an IDE

Informed Consent and IRBs



- Same regulatory requirements for obtaining informed consent and the IRB review process as for non-DCTs
- Investigators may obtain electronic informed consent from trial participants at their remote locations
- Recommend to the use a central IRB

Investigational Products: Drugs

- The nature of the drug should be considered when determining whether administration outside of a clinical trial site in a DCT is appropriate
 - Complexity of administration
 - Safety profile
 - Stage of drug development
- May be appropriate for local HCPs or trial personnel working remotely to administer the IP at local health care facilities or participants' homes
- Hybrid DCTs may be considered for drugs that require supervised but infrequent administration

Investigational Products: Devices



- Consider the type of medical device, its intended use, its instructions for use, and whether it is a significant risk or nonsignificant risk device
 - Is product suitable for home use?
 - Does product pose a risk to participants?
 - Does the use or administration require direct supervision?

Distribution of IP

- DCTs may allow for the direct distribution of investigational products to trial participants at their locations
- Protocols should describe
 - how the physical integrity and stability of the IP will be maintained during shipment to trial participants
 - how investigators will track and document that trial participants receive IPs
 - procedures that investigators or participants should use to return or dispose of unused IPs and how this will be documented

Shipping of IP



- Shipping containers should include clear instructions for handling and storing the IPs and instructions for returning unused IPs
- A central distribution service can be used to ship the IP to trial participants
- Sponsors and investigators must comply with applicable Federal, State, and international laws and regulations that address shipping IPs in their respective jurisdictions

Safety Monitoring Plan

- Should consider the decentralized nature of trial
 - Ensure adverse events (AE) are adequately captured and addressed
 - Provide guidance for participants on reporting/seeking care for AEs
- If remote administration or use of an IP causes safety issues, discontinue remote administration or use

Software Used in DCTs

- Software can be used to perform multiple functions to manage DCT operations
 - Training should be provided to all parties using software to support the conduct of DCT
 - Software programs that are used to produce and process trial records required by the FD&C Act and FDA regulations are subject to 21 CFR part 11
- Real-time video interactions, including telehealth, are not considered electronic records and are not subject to 21 CFR part 11

Docket Comments



Submit Comments by 08/01/2023

[Submit Comments Online](#)

Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number:
[FDA-2022-D-2870](#)

<http://www.regulations.govdocket/FDA-2022-D-2870>

DCT Trial vs. DCT Elements



Not “all or nothing”

- All trials can incorporate various DCT elements where appropriate
- DCT elements can range from relatively simple (e-consent) to complex (shipping of IP)
- Consider ways to make trial participation less burdensome by implementing DCT elements suitable for the context

Themes: FDA Guidance on DCTs

- Risk-adapted approach
 - What elements of decentralization are appropriate for a given investigation?
- Pre-specify decentralized elements
 - Documentation
- Regulatory requirements do not differ for DCTs
- *Meetings to discuss trials (DCT or otherwise) encouraged*

Thank you!



Acknowledgements:

- Paul Kluetz
- Timil Patel
- Harpreet Singh
- Nicole Drezner
- Richard Pazdur



U.S. FOOD & DRUG
ADMINISTRATION